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Aim: To assess target volume coverage during prostate image-guided radiotherapy based on
bony anatomy alignment and to assess possibility of safety margin reduction.
Background: Implementation of IGRT should inﬂuence safety margins. Utilization of cone-
beam CT provides current 3D anatomic information directly in irradiation position. Such
information enables reconstruction of the actual dose distribution.
Materials and methods: Seventeen prostate patients were treated with daily bony anatomy
image-guidance. Cone-beam CT (CBCT) scans were acquired once a week immediately after
bony anatomy alignment. After the prostate, seminal vesicles, rectum and bladder were
contoured, the delivered dose distribution was reconstructed. Target dose coverage was
evaluated by the proportion of the CTV encompassed by the 95% isodose. Original plans
employed a 1 cm safetymargin. Alternative plans assuming a smaller 7mmmargin between
CTV and PTV were evaluated in the same way. Rectal and bladder volumes were compared
with the initial ones. Rectal and bladder volumes irradiated with doses higher than 75Gy,
70Gy, 60Gy, 50Gy and 40Gy were analyzed.
Results: In 12% of reconstructed plans the prostate coverage was not sufﬁcient. The prostate
underdosage was observed in 5 patients. Coverage of seminal vesicles was not satisfactory
in 3% of plans. Most of the target underdosage corresponded to excessive rectal or bladder
ﬁlling. Evaluation of alternative plans assuming a smaller 7mm margin revealed 22% and
11% of plans where prostate and seminal vesicles coverage, respectively, was compromised.
These were distributed over 8 and 7 patients, respectively.Conclusion: Sufﬁcient dose coverage of target volumes was not achieved for all patients.
Reducing of safety margi
considered representative
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. Background
maging technology drives advancement in radiation ther-
py. Different styles of image-guided radiation therapy (IGRT)
re frequently discussed.1,2 Unpredictable prostate position
ariation is the challenge for comparison of different IGRT
trategies. Techniques of patient setup relative to external
eam’s isocenter have developed during the last decade.
istorically, skin marks and setup lasers have been used.
hese are not adequate surrogates for prostate position and
equire extensive safety margins, which are incompatible
ith the delivery of the high radiation doses above 70Gy
hich are currently used in routine practice.3,4 Planar X-ray
maging techniques have enabled registration with skeletal
natomy, but recent studies have shown a poor correlation of
rostate position and bony anatomy.5 Prostate location varia-
ions were studied relative to the adjacent bony anatomy by
challenkamp et al.6 with the conclusion that a signiﬁcant
nterfractional motion exists between the prostate and the
elvic bony anatomy. These move independently, therefore,
he pelvic bony anatomy should not be used as a surro-
ate for prostate motion. Authors also suggest that ﬁducial
arkers are stable within the prostate and allow signiﬁcant
argin reduction when used for on-line localization of the
rostate. The limited interuser variability and the marker
tability make markers an ideal surrogate for the prostate
osition.4 Another promising way of prostate image guidance
s the use of in-room CT – helical on-rail CT or cone-beam CT
CBCT) – which provides 3D anatomic information directly in
rradiation position. Compared to ﬁducial markers detected
ith planar imaging, the acquisition time is longer with CBCT
nd patient is exposed to a signiﬁcantly larger additional radi-
tion dose. Also the 3D image registration ismore difﬁcult and
ime-consuming.
Substantial positional variation of prostate over a 1-h
eriod is caused by a variety of factors. The most signiﬁcant
redictor for intrafraction prostate motion is the status of
ectal ﬁlling.7 A full rectal state is invariably associated with
obile gas pockets responsible for elevated levels of prostate
otion. While the apex is largely immobile, prostate motion
s well described by rotation, but does undergo deforma-
ion due to rectal distension.8 Effects of rectal motion during
rostate radiotherapy with regard to rectal dose and clinical
arget volume (CTV) dose coverage were studied by Sripadam
t al.9 This study revealed instances of insufﬁcient CTV cov-
rage.
IGRT systems provide more information than is required
or simple patient positioning. Utilization of cone-beam CT
CBCT) can provide 3D anatomic information directly in irra-
iation position. Such information enables reconstruction of
current dose distribution. CBCTwas evaluated for treatment
lanning by Yoo and Yin10 and Yang et al.11 with the conclu-
ion that CBCT could be used for veriﬁcation planning to verify
reatment delivery retrospectively.
Evaluation of the ‘dose of the day’ using post-treatment
BCT for IMRT prostate cancer patients with implantedmark-
rs was described by van Zijtveld et al.12 The actual IMRT
uence maps delivered to a patient were derived from mea-
ured EPID-images acquired during treatment. Retrospectivetherapy 1 7 ( 2 0 1 2 ) 134–140 135
IMRT dose reconstruction based on CBCT andMLC log-ﬁle was
described by Lee et al.13
2. Aim
The aim of the present study was to utilize the CBCT scans
acquired before treatment for dose reconstruction purposes
and hereby to assess target volume coverage during prostate
image-guided radiotherapy based on bony anatomy align-
ment.
3. Materials and methods
3.1. Patient characteristics
Seventeen patients with adenocarcinoma of the prostate
staged T2a–T3b N0 M0 were evaluated. Patients were treated
using intensitymodulated radiotherapy (IMRT) to the prostate
with simultaneous integrated boost to the proximal part of
seminal vesicles. Daily bony anatomy image-guidance was
performed based on 2 orthogonal kV images. In order to
assess target volume coverage, CBCT scans were acquired
once a week in the treatment position immediately after bony
anatomy alignment.
3.2. Validation of dose calculation on CBCT
A Siemens Somatom Sensation CT scanner (Siemens Medi-
cal Solutions, Erlangen, Germany) was used for acquisition of
CT images (512×512 matrix, 0.98mm pixel size, 3mm slice
thickness). CBCT imageswere acquired using VarianOn-board
imaging system (OBI®, Varian Medical Systems, Palo Alto, CA)
and reconstructed using about 700 images in a “half-fan” pro-
jection with a bowtie ﬁlter acquired over 360◦ rotation. For
CBCT reconstruction, 45 cm diameter and 12 cm axial length
with 3mm slice thickness and 512×512 matrix was used. The
technique used was 125kV, 80mA, 25ms.
The method to reconstruct the actually delivered dose
based on pretreatment CBCT was ﬁrst validated using phan-
tom measurements. Dose proﬁles were compared for CBCT
and CT images of inhomogeneous antropomorﬁc RANDO®
phantom (The Phantom Laboratory, Salem, NY, USA). The
images were imported into the EclipseTM treatment plan-
ning system, version 8.1 (Varian Medical Systems, Palo Alto,
CA). Plans based on CBCT and CT images were generated
using (1) one 10 cm×10 cm ﬁeld and (2) ﬁve coplanar IMRT
ﬁelds. 6MV photon energy was used. Dose calculations were
performed by a pencil beam convolution algorithm with Mod-
iﬁed Batho heterogeneity correction. The dose calculation
grid used was 0.25 cm. Dose was normalized to the isocenter
with a prescription of 2Gy. The resulting dose distributions
and depth dose proﬁles on the central beam axis were com-
pared.
3.3. Radiotherapy planning and deliveryIntensity modulated radiotherapy (sliding window technique)
withﬁve coplanarﬁelds to theprostateplus theproximal 2/3 of
seminal vesicles was planned and delivered. CT slices of 3mm
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Table 1 – Prescription doses for planning target volumes and acceptable doses for organs at risk.
Structure Prescription
Prostate (PTV2)
Prescribed dose 78Gy=mean dose for PTV2
Minimally 95% of the prescribed dose (i.e. 74.1Gy) to 95% of the PTV2
Maximal dose ≤107% of the prescribed dose (i.e. 83.5Gy)
Seminal vesicles
(PTV1–2)
Prescribed dose 72.15Gy
Minimally 95% of the prescribed dose (i.e. 68.5Gy) to 95% of the PTV1–2
Maximal dose ≤107% of the prescribed dose (i.e. 77.2Gy)
Rectum
Maximally 50% can receive 50Gy
Maximally 25% can receive 70Gy
Maximally 15% can receive 75Gy and maximally 15 cm3 can receive 75Gy
Maximum dose 78Gy
Bladder
Maximally 30% can receive 70Gy
Maximally 15% can receive 75Gy and maximally 15 cm3 can receive 75Gy
Maxithickness were acquired. Patients were scanned and treated
in a supine position with Dual Leg Positioner (Civco Medical
Solutions, IA, USA) to immobilize their legs and pelvis.
The patients were instructed to empty their rectum before
the planning CT as well as before each irradiation ses-
sion. Patients also obtained glycerin suppositories, but their
application was voluntary. Application of suppositories was
strongly recommended only when the planning CT had to be
repeated by reason of rectum volume. The planning CT scan
was repeated in case the rectumvolume exceeded 120 cm3 (for
organs at risk delineation see below). Patients were instructed
to have their bladders slightly ﬁlled at the time of plan-
ning CT. This can be achieved by drinking 500ml of water
45min before planning CT. Instructions for the rectum and
bladder ﬁlling management were similar at time of irradia-
tion.
CT images were transferred to the EclipseTM treatment
planning system. Clinical target volumes (CTVs) were delin-
eated as follows: CTV1 represents the prostate plus the
proximal part of seminal vesicles, CTV2 represents the
prostate alone, thus CTV1–2 represents the proximal part of
seminal vesicles. Then, planning target volumes (PTVs) were
created: to obtain the planning target volume for the prostate
(PTV2), a 10-mm margin was applied to CTV2 in all direc-
tions. PTV1 was constructed in the same manner. PTV1–2 was
obtained by subtraction PTV1–PTV2. Organs at risk (OARs) –
rectum and bladder – were delineated just 1 cm in excess of
PTV1 both in the cranial and caudal directions.
A ﬁve-ﬁeld intensity modulated radiotherapy (IMRT) with
simultaneous integrated boost using 6MV photons was used
to deliver 78Gy to PTV2 and 72.15Gy to PTV1–2 in 39 frac-
tions. This regimen corresponds to 2Gy/fr. and 1.85Gy/fr. to
the prostate and proximal part of seminal vesicles, respec-
tively. The IMRTplanwas optimized to fulﬁll criteria presented
in Table 1.
In order to evaluate the possibility of margin reduction,
alternative plans assuming a smaller 7mm margin between
the clinical and planning target volumeswere prepared. These
plans were not intended for irradiation, but were made for
reconstruction purposes. Alternative plans were optimized
for maximal OARs sparing allowed for PTV2 dose coverage
between 95 and 96%.mum dose 78Gy
3.4. On-treatment CBCT acquisition and assessment
Patients were treated using Varian Clinac® 2100C/D linear
accelerator equipped with On-board imager® (OBI) kV imag-
ing system version 1.3 with CBCT option. After an initial
skin marks setup, two orthogonal kV images were acquired
and patient’s position was corrected based on bony anatomy.
Immediately after the bony anatomy set-up, CBCT scan was
acquired. The resulting images were subsequently sent to the
EclipseTM TPS where the treatment isocenter was identiﬁed.
CTVs and OARs were outlined by a single observer at the same
range as on the planning CT. CBCT scans were acquired once a
week, during treatment fractions no. 2, 5, 10, 15, 20, 25, 30 and
35. CBCTswerenot used for set-up of the patient, just for retro-
spective analysis. Original treatment plan based on planning
CT was then reconstructed on each CBCT. Reconstruction of
the actually delivered dose distribution was performed based
on planned ﬂuences and MUs. The isocenter of the recon-
structed plan was set to the isocenter of the CBCT scan,
which corresponded to the online matched treatment isocen-
ter. Alternative plans assuming a smaller 7mm margin were
reconstructed in the same way.
3.5. DVH analysis
The reconstructed dose distributions were compared with
the planned dose distribution by evaluating the dose-volume
histograms (DVHs) for the prostate (CTV2), seminal vesicles
(CTV1–2), rectum and bladder. For the prostate and seminal
vesicles, the relative volumes that received at least 95% of the
prescribed dose were derived. Situations where less than 95%
of the CTV was covered by 95% of the prescribed dose were
considered as underdosed.
For each patient, variation coefﬁcients were calculated for
rectal and bladder volumes based on planning CT and CBCTs
together. Correlations between the delineated rectal volume
and relative rectal volume irradiated with doses higher than
75Gy, 70Gy, 60Gy, 50Gy and 40Gy were tested. Correlations
between delineated bladder volume and absolute volume irra-
diated with doses higher than 75Gy, 70Gy, 60Gy, 50Gy and
40Gy were tested similarly.
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Fig. 1 – Coverage by 95% of the prescribed dose: the upper part of the ﬁgure concerning the prostate (CTV2) and the lower
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.1. Validation of dose calculation on CBCT
omparison of dose distributions of CBCT-based andCT-based
lans using one conventional photon beam showed 1% differ-
nce in themaximumdose. Comparison of depth dose proﬁles
n the central beam axis showed the agreement better than
.3%. Higher difference was observed in the range of 2mm
elow the body surface, where the beamentered into the body.
Comparison of 5-ﬁeld IMRT dose distributions showed 0.2%
ifference in the maximum dose. Comparison of depth dose
roﬁles on central beam axis showed the agreement better
han 3%. Higher difference was observed in the range of 1 cm
elow the body surface, where the beamentered into the body.
.2. DVH analysis
umber of CBCT scans acquired for one patient during treat-
ent course was between 4 and 8, median was 6 scans. Total
umber of CBCT acquisitions was 103. Lower number of CBCT
cans than expected was caused by technical problems with
he OBI system or by excessive accelerator workload.ft and alternative 7-mm margin right.
There were 12 reconstructed plans, out of 103, where 95%
of the CTV2 was not covered by the 95% isodose, and these
were distributed over 5 patients. Sufﬁcient coverage of CTV1–2
was not achieved in 3 cases, and these were observed in
1 patient. Evaluation of alternative plans assuming a smaller
7mm margin revealed 23 of 103 cases of CTV2 underdosage
distributed over 8 patients and 11 cases of CTV1–2 under-
dosage distributed over 7 patients. Overall CTV coverage by
95% of the prescribed dose is shown in Fig. 1.
Variability of rectal and bladder volumes is shown in
Figs. 2 and 3, respectively. Variation coefﬁcients for rectal vol-
umes were between 0.05 (Patient 17) and 0.60 (Patient 15).
Maximum rectal volume observed was 267 cm3 (Patient 10),
which is more than three times higher than corresponding
planning CT volume (81 cm3). Variation coefﬁcients for blad-
der volumes were between 0.08 (Patient 17) and 0.48 (Patient
3).
As mentioned above, there were 5 patients with under-
dosed CTV2. This underdosage can be mostly explained by
excessive rectal or bladder ﬁlling:In Patient 3, the CTV2 underdosage was observed twice. In
the ﬁrst case the rectal volume was 192 cm3 (2 times larger
than initial volume) and in the second case the rectal vol-
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Fig. 2 – Comparison of rectal volume on CBCT scan (box
plot) with planning CT scan (red cross). The box represents
the 25th and 75th percentiles, with the central line showing
the median value. Two lines extending from the central box
of maximal length 3/2 the interquartile range but not
extending past the range of the data. Outliers are points
Fig. 3 – Comparison of bladder volume on CBCT scan (box
plot) with planning CT scan (red cross). The boxthat lie outside the extent of the previous elements.
umewas 131 cm3 (1.5 times larger than initial volume). Both of
these volumes were higher than our limit value for planning
CT rectal volume (120 cm3).
In Patient 5, the CTV2 underdosage seems to be caused by
bladder ﬁlling.
In Patient 10, the CTV2 underdosage was caused by too high
rectal volume of 267 cm3 (more than three times higher than
initial CT rectal volume). This value was the biggest observed
as well. Prostate was signiﬁcantlymoved anteriorly out of 95%
isodose.
In Patient 14, the CTV2 underdosage was observed in all ﬁve
CBCT acquisitions. We consider the initial rectal volume to
be representative for subsequent CBCT rectal volumes (Fig. 2).
The underdosage can be explained by a higher bladder vol-
ume (115–164 cm3) than the volume at initial planning CT
scan (92 cm3). In these cases CBCT bladder volumes represent
125–178% of the initial bladder volume (Fig. 3).
In Patient 15, the CTV2 underdosage was observed three
times. In the ﬁrst case the rectal volume was 157 cm3 (more
than 3 times larger than initial volume) and in the second
case the rectal volume was 91 cm3 (almost 2 times larger than
initial volume).
Correlations between rectal volume (bladder volume resp.)
and its volume irradiated to various speciﬁc doses are summa-
rized in Table 2. A medium correlation can be seen between
rectal volume and the proportion of rectal volume irradiated
with doses higher than 75Gy.
5. DiscussionFeasibility of CBCT-based dose calculation was evaluated pre-
viously by Yoo and Yin10 by comparing CBCT-based treatment
plans to conventional CT-based plans for both phantoms andinterpretation is the same as in Fig. 2.
patients. CBCT-based treatment plans were dosimetrically
comparable to CT-based treatment plans: up to 3% of dosi-
metric errors were observed to occur in the plans for the
inhomogeneous phantom. Usability of CBCT for dose recon-
struction was also investigated by Yang et al.11 For the static
phantom, doses computed based on conventional CT and
CBCT agreed to within 1%. Based on prostate patient and
lung patient studies, authors concluded that the CBCT can be
employed directly for dose calculation for a disease site such
as the prostate, where there is little motion artefact. Our com-
parison of dose distributions computed on an inhomogenous
antropomorﬁc phantom revealed that CBCT-based plans were
comparable to CT-based plans, thus the CBCT can be used to
verify treatment delivery retrospectively.
A daily cone-beam CT study of the effect of rectal motion
on CTV coverage during prostate radiotherapy was performed
by Sripadamet al.9 CBCT scanswere acquired from15 patients
immediately after daily treatment. Daily off-line electronic
portal imaging veriﬁcation of bony anatomy positioning was
carried out, with an intervention level of 5mm. To obtain the
PTV, a 10-mm margin was applied in all directions, except
posteriorly where a 7-mmmarginwas added. A four-ﬁeld con-
formal technique was used with the PTV covered by the 95%
isodose. Fields were shaped with multileaf collimators with
a penumbra margin of 7mm. Sripadam revealed instances of
insufﬁcient CTV coverage occurring in 38% of the fractions
delivered to six patients. These only occurred in the upper
regions corresponding to the prostate base and seminal vesi-
cles. Sripadam indicated no statistical correlation between
initial rectal volume from planning CT scan and insufﬁcient
coverage. However, for patients with large planning rectal
volumes, mean dose to the rectum was less than predicted,
whereas for patients with small planning rectal volumes,
mean dose was greater than predicted.
In a recent paper, Hatton et al.16 assessed the accu-
racy of the initial CT plan dose-volume histograms for the
prostate, rectumandbladder by comparison todelivereddoses
determined from CBCT scans acquired immediately following
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 134–140 139
Table 2 – Pearson’s correlation coefﬁcient between rectal volume (bladder volume resp.) and its volume irradiated to
various speciﬁc doses.
Rectal volume Bladder volume
10mm margin 7mm margin 10mm margin 7mm margin
V75 (%) 0.50 0.45 V75 (cm3) −0.01 −0.11
V70 (%) 0.43 0.42 V70 (cm3) 0.11 0.00
V60 (%) 0.28 0.30 V60 (cm3) 0.22 0.11
V50 (%) 0.14 0.15 V50 (cm3) 0.33 0.20
V40 (%) −0.08 −0.20 V40 (cm3) 0.46 0.33
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5. Balter JM, Sandler HM, Lam K, et al. Measurement of prostate
movement over the course of routine radiotherapy using
implanted markers. Int J Radiat Oncol Biol Phys 1995;31:113–8.Abbreviations: Vdose (%), relative organ volume receiving higher dose
than speciﬁed.
onformal treatment delivery. For the group of 12 prostate
atients, daily online implanted ﬁducial guidance was carried
ut, with a uniform margin of 7mm around CTV to determine
he PTV. Prostate dose coverage was assessed by the propor-
ion of the CTV fully encompassed by the 95% and 98% isodose
ines. Four patients showedmarginally compromisedCTVcov-
rage by the 95% isodose at all CBCT plans. Hatton reports 88%
f all planswheremore than95%of theprostate volume is cov-
red by the 98% isodose. Hatton suggests that margin size of
mm is not enough to ensure sufﬁcient prostate coverage at
ll treatment levels.
Our group of 17 patients is not large enough to represent
ntire patient population, but it is comparable with previously
ublished studies.13–15 However, it was helpful to identify
eneral issues of the CTV insufﬁcient dose coverage. Using
MRT techniquewith 10-mmCTV-to-PTVmargin, we observed
nsufﬁcient prostate coverage in 12 cases distributed over ﬁve
atients. Converted into the proportion of delivered fractions
or purpose of comparison with the Sripadam’s study,9 this
epresents 43% of the fractions delivered to ﬁve patients. How-
ver, the comparison can be affected by a lower number of
BCT scans (range 4–8 scans) than in Sripadam’s study (range
0–16 scans). We observed similar behaviour of prostate dis-
lacement in cases of prostate insufﬁcient coverage caused by
xcessive rectal volume – prostate apex seems to be relatively
xed, while the prostate base undergoes rotationalmovement
round the apex anteriorly.8,9
UsingHatton’smethodology of counting cases fully encom-
assed by the 95% isodose, i.e. 100%of theCTV2 should receive
5% of the prescribed dose, our results of prostate coverage
sing 10-mm margin and bony anatomy alignment are poorer
han the Hatton’s using 7-mm margin and implanting ﬁdu-
ial guidance. We observed 23% of all plans where the CTV2 is
ot fully encompassed by the 95% and these were distributed
ver 9 patients. However, in half of these cases the CTV2 cov-
rage was compromised marginally, where more than 95% of
he CTV2 was covered by the 95% isodose (Fig. 1, upper left).
oreover, our CBCT scans were acquired before treatment. If
he CBCTswere acquired after treatment, the results would be
orse in terms of prostate coverage because of the potential
ntrafraction motion.17. Conclusions
ur ﬁndings are in agreement with the literature data and
onﬁrm insufﬁcient prostate coverage during IGRT based onspeciﬁed; Vdose (cm3), absolute organ volume receiving higher dose
bony anatomy alignment. Moreover, reconstruction of dose
distribution assuming a smaller margin between clinical and
planning target volumes leads to signiﬁcantly worse results
in prostate coverage. Initial rectal and bladder volumes can-
not be considered representative for subsequent treatment.
Especially excessive rectal ﬁlling can cause prostate move-
ment out of irradiated volume.We suggest that clearly deﬁned
diet instructions could be helpful. Reproducible bladder ﬁll-
ing could be achieved by asking patients to empty their
bladder 30min before planning CT examination and each
treatment fraction and then to drink 500ml of water.7 Of
course, advanced IGRT techniques like CBCT and ﬁducials
should be considered for daily prostate alignment.
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